Get started
Author

Federico Cappuzzo

ORCID: 0000-0002-6295-6767
Observed ORCID: 0000-0002-6295-6767
OpenAlex ID: A5122012297
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC
2026 · Mehmet Altan, Vishal Navani, et al. · Figshare
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
2026 · Dongsheng Yue, Federico Cappuzzo, et al. · Future Oncology
PDF
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
2026 · Dongsheng Yue, Federico Cappuzzo, et al. · Figshare
Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
2026 · Xiuning Le, Antonio Passaro, et al. · Figshare
Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
2026 · Xiuning Le, Antonio Passaro, et al. · Future Oncology
PDF
A Plasma-first Framework for Early Molecular Profiling in Suspected Advanced Nsclc: Preliminary Results from the Prospective Multicenter Innova-WP4 Study
2026 · Francesco Coletta, Federico Bartoccini, et al. · The Journal of Liquid Biopsy
PDF
Data from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S3 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S6 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S7 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S4 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S5 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Table S2 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S9 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Figure S8 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Supplementary Table S1 from The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial
2026 · Andrea Botticelli, Chiara Cremolini, et al.
Works count: 18
Citation count:
H-index:
I10-index:
Year
Topic
Type